Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent

PURPOSE: Overall, ~65% of patients diagnosed with advanced ovarian cancer (OC) will relapse after primary surgery and adjuvant first-line platinum- and taxane-based chemotherapy. Significant improvements in the treatment of OC are expected from the development of novel compounds having combined cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Rickardson, Linda, Kutvonen, Emma, Orasniemi, Satu, Högberg, Marita, Kallio, Marko J, Rehnmark, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417661/
https://www.ncbi.nlm.nih.gov/pubmed/28496304
http://dx.doi.org/10.2147/DDDT.S133189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417661/
https://www.ncbi.nlm.nih.gov/pubmed/28496304
http://dx.doi.org/10.2147/DDDT.S133189

Ejemplares similares